Nasdaq-listed biopharmaceutical company, Gilead Sciences, is acquiring Germany-based Tubulis, for a total deal value of up to US$5bn. Under the terms of the agreement, Gilead will acquire all of the outstanding…
Germany: Gilead significantly expanding ADC capabilities with agreement to acquire Tubulis for up to US$5bn
…
…






